FDA在2026年PDA/FDA联合监管会议剖析无菌工艺缺陷并报告无菌设施趋势
无菌设施趋势:洞察与现代化机会
FDA消费者安全官Jason F. Chancey在2026年PDA/FDA联合监管会议报告《无菌设施趋势:洞察与现代化机会》,把无菌工艺设计原则与检查所见的设施及行为缺陷逐项对应。
FDA 在 PDA/FDA 联合监管会议上剖析无菌工艺处理缺陷
无菌设施趋势:洞见与现代化机会
FDA Highlights Aseptic Processing Pitfalls at PDA/FDA Conference
来源 / Source:BioPharm International(biopharminternational.com)
URL:https://www.biopharminternational.com/view/fda-aseptic-processing-pitfalls-pda-fda-conference
发布日期 / Published:2026-09-16
作者 / Author:Feliza Mirasol
讲者 / Speaker:Jason F. Chancey, PharmD(FDA 药品审评与研究中心合规办公室生产质量办公室消费者安全官)
场合 / Venue:PDA/FDA Joint Regulatory Conference 2026(2026 年 9 月 14 至 16 日,华盛顿特区),报告《Sterile Facility Trends: Insights and Modernization Opportunities》
说明 / Note:原文两条参考文献随文译出。
要点
Key Takeaways
Contemporary aseptic strategies emphasize automation, integrated unit operations, and physical separation using RABS/isolators to protect ISO 5 air quality and reduce manual intervention risk.
当代无菌策略强调自动化、集成的单元操作,以及用 RABS/隔离器实现物理隔离,以保护 ISO 5 空气质量并降低人工干预风险。
Maintenance failures such as taped diffusion membranes, degraded gaskets, nonfunctional pressure gauges, and misplaced bellows can compromise barrier integrity despite otherwise sound facility design.
用胶带固定的扩散膜、老化密封垫、失效压差表、错位波纹管这类维护失效,即便设施设计本身完好,也会损害屏障完整性。
Operational deviations, including reaching over open turntables and adding “mini-doors” for manual access, erode Grade A separation and increase contamination hazards.
伸手越过敞开转盘、加装供人工进出用的“小门”这类操作偏差,会侵蚀 A 级隔离并加重污染危害。
Airflow smoke studies often fail due to inappropriate tracer properties, unrealistic velocities/placements, non-representative setups, and unaddressed disturbances such as short-circuiting flow or vortices.
气流烟雾研究的常见失败原因:示踪介质特性不当、流速与布置不真实、装置不具代表性,以及短路气流或涡流等扰动未获处理。
A recent warning-letter case cited water deadlegs with recurrent gram-negative recoveries, delayed leak-test remediation during production, fiber-shedding materials in ISO 5 areas, and permissive BI survivor acceptance criteria.
一封近期警告信案例引用了如下缺陷:死水段反复检出革兰阴性菌、生产期间泄漏测试整改拖延、ISO 5 区域使用掉纤维材料,以及过宽的生物指示剂存活体可接受标准。
FDA’s consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
FDA 消费者安全官 Jason Chancey 详述了无菌设施缺陷背后的真实检查发现,例如用胶带修补的密封垫与被推迟的复测。
At the 2026 PDA/FDA Joint Regulatory Conference, Jason F. Chancey, PharmD, consumer safety officer in the Office of Manufacturing Quality within FDA’s Center for Drug Evaluation and Research Office of Compliance, presented “Sterile Facility Trends: Insights and Modernization Opportunities,” at which he paired core design principles for aseptic processing with real-world examples of facility and behavioral shortcomings the agency has observed during inspections.¹
在 2026 年 PDA/FDA 联合监管会议上,FDA 药品审评与研究中心(CDER)合规办公室生产质量办公室消费者安全官 Jason F. Chancey(PharmD)作报告《无菌设施趋势:洞见与现代化机会》(Sterile Facility Trends: Insights and Modernization Opportunities),把无菌工艺处理的核心设计原则,与该机构在检查中观察到的设施与行为层面真实缺陷逐一配对。¹
关键事实
Key Facts
Speaker: Jason F. Chancey, PharmD, FDA CDER Office of Compliance
讲者:Jason F. Chancey(PharmD),FDA CDER 合规办公室。
Session: “Sterile Facility Trends: Insights and Modernization Opportunities”
报告:《无菌设施趋势:洞见与现代化机会》。
Event: PDA/FDA Joint Regulatory Conference 2026 (Sept. 14-16, 2026, Washington, DC)
场合:2026 年 PDA/FDA 联合监管会议(2026 年 9 月 14 至 16 日,华盛顿特区)。
Core theme: Modern aseptic design (automation, isolation) vs legacy manual/partial-barrier approaches
核心主题:现代无菌设计(自动化、隔离)与遗留的人工/部分屏障模式的对比。
Separation spectrum discussed: LAF hood → open/closed RABS → open/closed isolators
讨论的隔离谱系:层流罩(LAF hood)→ 开放/密闭式 RABS → 开放/密闭式隔离器。
Key maintenance failures shown: taped gaskets, nonfunctional pressure gauges, membrane discoloration
展示的主要维护失效:用胶带修补的密封垫、失效的压差表、滤膜变色。
Airflow study issues: unsuitable tracer media, mispositioned tracers, unacknowledged disturbances
气流研究问题:示踪介质不当、示踪位置错误、未获确认的扰动。
Warning letter case study: 47 microbial recoveries over ~2 years; 14 exceeded action limit
警告信案例:约两年内 47 次微生物检出,其中 14 次超出行动限。
Additional findings: 18-day retest gap (July 1-19, 2025), fiber-shedding materials, inadequate BI validation
其他发现:18 天复测空窗(2025 年 7 月 1 至 19 日)、掉纤维的材料、不充分的生物指示剂(BI)验证。
Regulatory context: Findings drawn from a redacted FDA warning letter cited as illustrative
监管背景:检查发现引自一份脱敏的 FDA 警告信,用作示例。
一、什么设计原则指导现代无菌工艺设施?
What design principles guide modern aseptic processing facilities?
Dr Chancey outlined design principles for modern aseptic facilities, including optimizing cleanroom layout, operational space, air volume, and material and process flow; protecting the aseptic line with robust isolator or barrier technology to prevent ingress of lower-quality air into the ISO 5 (Class 100) area; minimizing exposure of sterile product components to contamination hazards; and limiting or eliminating manual manipulations through automation and integration.¹ He contrasted a 20th-century approach built on manually intensive unit operations and partial barriers with a 21st-century approach built around automation, integration, and physical separation.
Chancey 博士列出现代无菌设施的设计原则,包括:优化洁净室布局、操作空间、风量以及物料与工艺流向;用可靠的隔离器或屏障技术保护无菌产线,防止质量较低的空气进入 ISO 5(百级,Class 100)区域;尽量减少无菌产品组分暴露于污染危害;以及通过自动化与集成来限制或消除人工操作。¹ 他把建立在人工密集单元操作与部分屏障之上的 20 世纪模式,与围绕自动化、集成和物理隔离构建的 21 世纪模式作了对比。
The modern 21st century approach places emphasis on open-air laminar flow hoods and open and closed restricted-access barrier systems (RABS) as well as open and closed isolators. Dr Chancey noted that RABS represents “today’s typical minimum level of separation” in current aseptic operations.¹,² He also presented illustrative data suggesting process error rates can decline from roughly 2% toward 0% as automation increases, underscoring the rationale for automating manual steps wherever feasible.¹
现代 21 世纪模式的重点,是开放式层流罩、开放与密闭式限制进出屏障系统(RABS),以及开放与密闭式隔离器。Chancey 博士指出,在当前无菌作业中,RABS 代表“今天典型的最低隔离水平”。¹,² 他还给出示意性数据:随着自动化程度提高,工艺差错率可从约 2% 向 0% 下降,以此说明凡是可行的手工步骤都应自动化的理由。¹
图:操作人员在无菌隔离器内进行干预作业。
二、FDA 检查员发现了哪些设施维护失效?
What facility maintenance failures did FDA inspectors find?
Using inspection photographs to show how facility maintenance can undermine even well-designed barrier systems, Dr Chancey highlighted examples such as detached tape used to secure a diffusion membrane inside a barrier system and an inflatable isolator door gasket repaired with tape rather than replaced. Other maintenance examples included foam cuffs and tape found inside isolators, nonfunctional pressure-differential gauges observed during active batch manufacture, discoloration on a diffusion membrane directly above filling equipment, and silicone bellows found improperly positioned with unexplained discoloration.¹
Chancey 博士用检查现场照片说明,设施维护如何足以瓦解设计良好的屏障系统。他展示的例子包括:屏障系统内部用已脱落的胶带固定扩散膜;隔离器充气门密封垫用胶带修补而非更换。其他维护问题还有:隔离器内部发现泡沫护套与胶带;在批次生产进行期间观察到压差表失效;灌装设备正上方的扩散膜变色;硅胶波纹管位置不当且变色原因不明。¹
Dr Chancey also flagged behavioral and design lapses on the line itself, including an operator reaching over an open vial-loading turntable and a mini-door retrofitted into a barrier system to enable manual interventions into the Grade A space, a modification that can compromise the separation the barrier was designed to provide.¹
Chancey 博士同时指出产线自身的行为与设计疏失,包括操作人员伸手越过敞开的西林瓶装载转盘,以及在屏障系统上加装“小门”(mini-door)以便对 A 级区域进行人工干预;这种改动会破坏屏障本应提供的隔离。¹
三、嵌入式洁净室与气流研究有哪些常见陷阱?
What are common pitfalls in drop-in cleanrooms and airflow studies?
Turning to drop-in cleanrooms, prefabricated enclosures sometimes used to support aseptic processing, Dr Chancey emphasized a soft-walled cleanroom with a damaged, degraded ceiling and a horizontal flow hood presented as providing an ISO 5 environment despite visible imperfections.¹ He drew attention to airflow visualization, or smoke, studies used to confirm that unidirectional airflow protects critical processing areas.
谈到嵌入式洁净室(drop-in cleanrooms,即有时用于支持无菌工艺的预制围护结构)时,Chancey 博士重点展示了一间软墙洁净室:吊顶破损老化,却与一台水平流罩一起被呈现为可提供 ISO 5 环境的配置,可见缺陷明显。¹ 他随后讲的是气流可视化(烟雾)研究,这类研究用于确认单向流能否保护关键工艺区域。
He described 5 recurring deficiencies: tracer media lacking sufficient buoyancy or dissipating too quickly to be useful; tracer velocity too fast to represent actual conditions; tracer media not positioned near the intervention under evaluation; equipment or interventions not representative of commercial conditions; and airflow disturbances left unacknowledged in study conclusions. Examples included a tracer manifold positioned inches from the equipment being evaluated—with tracer media pooling on surfaces rather than demonstrating airflow; short circuit airflow moving from the Grade A space inside a barrier system directly into the surrounding Grade B space; and an unrecognized vortex forming and collapsing over a vibratory stopper bowl.¹
他列举了 5 类反复出现的缺陷:示踪介质浮力不足或消散过快,失去指示作用;示踪介质流速过快,不能代表实际工况;示踪介质没有布置在被评估干预点附近;设备或干预不代表商业化生产条件;以及气流扰动未在研究结论中得到确认。实例包括:示踪歧管布置在距被评估设备仅数英寸处,示踪介质在表面积聚,而不是显示气流走向;短路气流从屏障系统内部的 A 级空间直接进入周边 B 级空间;以及在一台振动式塞料斗(vibratory stopper bowl)上方形成未被识别、随后坍塌的涡流。¹
图:无菌灌装线设备特写。
四、FDA 的警告信揭示了无菌生产的哪些问题?
What did FDA's warning letter reveal about sterile manufacturing?
Dr Chancey closed with a case study drawn from a recent FDA warning letter spanning 4 categories of deficiencies. On microbiological contamination, the letter described extended water deadlegs used for equipment cleaning, which are known to cause stagnation and excessive microbial growth. Between June 2023 and September 2025, routine testing identified at least 47 microbial recoveries, including 14 exceeding the firm’s action limit, with repeated recovery of gram-negative, biofilm-forming organisms, including Sphingomonas, Methylobacterium, Bradyrhizobium, and Ralstonia species, he noted. The firm’s corrective action plans failed to address the underlying piping design, he added.¹
Chancey 博士最后以一封近期 FDA 警告信为案例收尾,该信涵盖 4 类缺陷。在微生物污染方面,信中指出用于设备清洁的过长死水段(water deadlegs),这类结构已知会造成水流停滞与微生物过度繁殖。他指出,2023 年 6 月至 2025 年 9 月间,常规检测至少检出 47 次微生物,其中 14 次超过该企业的行动限,并反复检出革兰阴性、可形成生物膜的微生物,包括鞘氨醇单胞菌属(Sphingomonas)、甲基杆菌属(Methylobacterium)、慢生根瘤菌属(Bradyrhizobium)与雷尔氏菌属(Ralstonia)。他补充说,该企业的纠正措施计划未能触及根本的管道设计问题。¹
On equipment integrity testing, the letter described a program that permitted critical components to fail leak testing multiple times before requiring replacement, with retesting sometimes delayed to a later date rather than performed the same day. In one instance, a component failed testing on July 1, 2025, and did not pass a retest until July 19, 2025, an 18-day gap during which the firm’s production schedule showed batches of drug product were manufactured using that component before its integrity was confirmed.¹
在设备完整性测试方面,信中描述的规程允许关键部件在多次泄漏测试失败后才要求更换,复测有时被推迟到以后的日期而非当天进行。其中一个实例中,某部件 2025 年 7 月 1 日测试失败,直到 2025 年 7 月 19 日才通过复测,中间 18 天的空窗期内,该企业的生产计划显示多批药品在部件完整性得到确认之前已使用该部件完成生产。¹
On material suitability, investigators observed fibers shedding from protective equipment covers inside critical aseptic filling areas, a recurring issue despite a prior customer complaint about a non-pharmaceutical-grade material, Dr Chancey pointed out.¹ On chemical decontamination, the letter cited a multiyear trend of positive biological indicator recoveries during decontamination cycle validation and acceptance criteria that inappropriately permitted multiple biological indicator survivors per cycle.¹
在物料适用性方面,Chancey 博士指出,调查人员在关键无菌灌装区域内观察到防护设备罩掉落纤维;此前已有客户投诉该材料为非药用级,问题仍反复出现。¹ 在化学去污染方面,信中引用了去污染周期验证期间生物指示剂阳性检出的多年趋势,以及不当地允许每个周期出现多个生物指示剂存活体的可接受标准。¹
The PDA/FDA Joint Regulatory Conference 2026 is taking place September 14-16, 2026, in Washington, DC.
2026 年 PDA/FDA 联合监管会议于 2026 年 9 月 14 至 16 日在华盛顿特区举行。
参考文献
References
1. Chancey JF. Sterile facility trends: insights and modernization opportunities. Presented at: PDA/FDA Joint Regulatory Conference 2026; September 14-16, 2026; Washington, DC.
1. Chancey JF. 无菌设施趋势:洞见与现代化机会。发表于:2026 年 PDA/FDA 联合监管会议;2026 年 9 月 14 至 16 日;华盛顿特区。
2. FDA. Guidance for Industry, sterile drug products produced by aseptic processing—current good manufacturing practice. (CDER, CBER, October 2024). Accessed September 16, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice
2. FDA.《行业指南:经无菌工艺生产的无菌药品:现行药品生产质量管理规范》(CDER、CBER,2024 年 10 月)。访问日期 2026 年 9 月 16 日。https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice
— 完 —
来源:小南AI实验室 · mp.weixin.qq.com